Last reviewed · How we verify
Tacrolimus prolonged release — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Tacrolimus prolonged release (Tacrolimus prolonged release) — Astellas Pharma Europe Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tacrolimus prolonged release TARGET | Tacrolimus prolonged release | Astellas Pharma Europe Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tacrolimus prolonged release CI watch — RSS
- Tacrolimus prolonged release CI watch — Atom
- Tacrolimus prolonged release CI watch — JSON
- Tacrolimus prolonged release alone — RSS
Cite this brief
Drug Landscape (2026). Tacrolimus prolonged release — Competitive Intelligence Brief. https://druglandscape.com/ci/tacrolimus-prolonged-release. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing